News

Keep up with the latest headlines in dermatology from the past week, including UK efforts to address skin cancer disparities in skin of color, efficacy of a "virtual biopsy," and more.

ICYMI, this week we had news about Rosacea Awareness Month, topical pravibismane in diabetic foot ulcer infections, and more.

Risankizumab demonstrated the highest efficacy in PASI90 responses among analyzed IL-23 inhibitors.

Earlier this week, we shared our first Rosacea Awareness Month quiz. Review the answers and your responses below.

Treatment also shifted the expression of key biomarkers in atopic dermatitis toward non-lesional levels, according to a recent study.

To properly execute loss harvesting and reinvestment properly, without running afoul of Internal Revenue Service rules, it is crucial that one works with a professional adviser experienced in these matters.

This Rosacea Awareness Month, take a look at previous coverage from 2024.

A matching-adjusted indirect comparison found that some patients with PsA are more likely to achieve long-term treatment outcomes with bimekizumab.

In one study, researchers were unable to detect any changes in the gut microbiome of patients treated with tapering dose of steroids or a probiotic mixture.

Diagnostic accuracy of lesions was enhanced with combined dermoscopy and reflectance confocal microscopy, according to one study.

Zoe Diana Draelos, MD, provides answers to the top 5 questions about neurocosmetics patients may have.

Miranti presented tips on handling denial hurdles and how to ensure patients receive access to the treatments they need.

Study participants in the treatment group experienced an observable and significant decrease in melanin index scoring.

From our April cover feature: Take an in-depth look at the basis of Valisure's benzene testing methods and practical recommendations for clinicians from Christopher Bunick, MD, PhD.

Combining fire needle therapy with a 308 nm excimer laser for vitiligo treatment, as per a recent meta-analysis, was deemed both safe and effective.

MoonLake’s sonelokimab is being evaluated for hidradenitis suppurativa, psoriasis, and psoriatic arthritis.

Mona Gohara, MD, explained the importance of the products' impact on the skin barrier.

According to 2 studies, this model has demonstrated the potential to assist in developing treatment and monitoring plans for early-stage melanomas.

Loretta Fiorillo, MD, FRCPC, reviews key data points from the phase 3 SPROUT study.

Dermatology Times is pleased to introduce our Spring Editor in Chief, Aaron Farberg, MD, with a snapshot of his involvement in the dermatology space.

This Rosacea Awareness Month, we have compiled a list of resources for clinicians to share with their rosacea patients.

This week’s collection of the latest dermatologic studies covers circulating tumor DNA in advanced cSCC, targeting IL-13 with tralokinumab in AD, a pediatric lymphoplasmocytic plaque case report, and skin of color reporting in randomized controlled trials focusing on SCC.

In an introduction to our April publication, explore an overview of topics covered in this issue and an introduction to our Spring Editor in Chief, Aaron Farberg, MD.

Data was recently published in the International Wound Journal supporting positive outcomes in moderate or severe ulcers.

Christopher Bunick, MD, PhD, delves into current data and guidelines to consider when creating custom treatment plans for patients with atopic dermatitis.

Click here to read more and answer our quiz questions in recognition of Rosacea Awareness Month.

Keep up with the latest headlines in dermatology from the past week, including the launch of an expanded job board for dermatology support roles, CMS and Incyte's collaboration for povorcitinib in China and Southeast Asia, and more.

ICYMI, this week we had news about Ycanth's J-code launch, highlights from Diversity in Dermatology, bimekizumab's accepted sBLA for HS, and more.

Gil Yosipovitch, MD, discusses the correlation between increased BNP levels and chronic pruritus of unknown origin.

Three distinct congresses known as RAVE (Revolutionizing Atopic Dermatitis, Alopecia Areata, and Vitiligo) will be held June 8-10, in Chicago, Illinois.